EHA 2015 | ENDEAVOR trial: Carfilzomib and dexamethasone for relapsed multiple myeloma

Jesús San Miguel

At the 20th Congress of the European Hematology Association (EHA), Jesús F. San Miguel, MD, of the Clínica Universidad de Navarra, Navarra, Spain, discusses the results of the multicenter, open-label, randomized, phase 3 ENDEAVOR trial of carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed multiple myeloma.

Share this video  
Related videos
Myeloma XI trial: increased progression-free survival
Charlotte Pawlyn
Pivotal STORM study: selinexor for penta-refractory multiple myeloma
Joshua Richter
Current challenges for multiple myeloma therapy: 2, 3, 4-drug combinations
Joshua Richter
Multiple myeloma musings: highlights from 2018 data
Joshua Richter
An exciting era for CAR T-cell therapy
Mohamad Mohty
Multiple Myeloma
Bortezomib, Carfilzomib, Dexamethasone
EHA 2015
11th June 2015
More from Jesús San Miguel
Subgroup analysis of the PANORAMA 1 trial of panobinostat for multiple myeloma
ELOQUENT-2 trial: Elotuzumab for relapsed or refractory multiple myeloma
Early treatment and novel therapeutic targets for multiple myeloma
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals